I spoke on the phone with Philip Daffas this morning who was kind enough to respond to my missed call earlier. This mornings quarterly is very positive, everything is on track and the business is managing its finances well.
A few points:
- The dementia app received great feedback from a variety of industry professionals. Daffas was surprised at their response and they even found settings where the app would be beneficial they didn't even think of!
- The nViso agreement extension announcement is very imminent beyond 2019. They have actually expanded their scope of contracts from 3 to 5, looks like to me its with lawyers waiting on signing.
- Daffas mentioned to me he is very excited to be working with IBM and the opportunities which may come out broadening into other medical applications using artificial intelligence. Obviously the most significant commercial opportunity is with the dementia app this year, but watch this space.
- The Childrens app database compilation is still occurring through their research firm in Europe, development will be later this year most likely whilst waiting for approvals. Its a 2018 commercial event.
- ePat were always aiming to do roadshows, however they wanted to finalise their first version dementia app (which has now been done) so investors can play around with the app instead of the company rocking up with slides. Major improvements to the app have been made including a selfie mode along with lighting indicators. Quite a robust tool.
- They will be presenting in June at a conference in the Gold Coast, potentially along with other East Coast locations. I mentioned TechKnow and they will be planning to be there in October in Sydney, Melbourne and Brisbane.
All in all its looking very bright, I have been looking at a variety of spec stocks and none stack up the way EPT does in the near term.
EPT Price at posting:
3.0¢ Sentiment: Buy Disclosure: Held
